MeiraGTx Holdings plc in connection with Sanofi’s strategic investment in MeiraGTx and its gene regulation technology

On October 30, 2023, MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced strategic updates, including an agreement with Sanofi pursuant to which Sanofi will make a $30 million strategic investment in the Company, and receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation (I&I) and Central Nervous System (CNS) targets, as well as for GLP-1 and other gut peptides for metabolic disease, and for MeiraGTx’s Phase 2 Xerostomia program. In addition, MeiraGTx has been approached by multiple parties with strategic interest in different assets of the Company and is actively pursuing these options.

Wachtell Lipton is serving as legal advisor to MeiraGTx.